Technology
Health
Biotechnology

Xenon Pharmaceuticals

$9.81
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

-$0.61 (-5.85%) Today
$0.00 (0.00%) After Hours

Why Robinhood?

You can buy or sell XENE and other stocks, options, ETFs, and crypto commission-free!

About

Xenon Pharmaceuticals, Inc. engages in discovering and developing therapeutics to improve the lives of patients with neurological disorders. It focuses on the treatment of epilepsy. Read More Its products include XEN496, XEN1101, XEN901, and XEN007. The company was founded by Simon Neil Pimstone, Johannes J. P. Kastelein, and Michael R. Hayden on November 5, 1996 and is headquartered in Burnaby, Canada.

Employees
92
Headquarters
Burnaby, British Columbia
Founded
1996
Market Cap
252.61M
Price-Earnings Ratio
—
Dividend Yield
0.00
Average Volume
185.57K
High Today
$10.48
Low Today
$9.63
Open Price
$10.42
Volume
91.14K
52 Week High
$15.92
52 Week Low
$4.45

Collections

Technology
Health
Biotechnology
Therapy
2014 IPO
Canada
North America

News

MarketBeatMar 7

Stock Price, News, & Analysis for Xenon Pharmaceuticals

Xenon Pharmaceuticals Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutics to treat patients with neurological disorders in Canada. The company uses Extreme Genetics, a core enabling discovery platform for the discovery of validated drug targets by studying rare human diseases with extreme traits, including diseases caused by mutations in ion channels, known as channelopathies. It clinical development pipeline includes XEN1101, a Kv7 potassium channel opener for the treatment...

11
Seeking AlphaMar 6

Xenon Pharmaceuticals (XENE) CEO Simon Pimstone on Q4 2018 Results - Earnings Call Transcript

Xenon Pharmaceuticals (NASDAQ:XENE) Q4 2018 Results Earnings Conference Call March 6, 2019 4:30 PM ET Company Participants Jodi Regts - VP, Corporate Affairs and IR Simon Pimstone - CEO Ian Mortimer - President and CFO Conference Call Participants Stephen Willey - Stifel Maurice Raycroft - Jefferies Operator Good day, ladies and gentlemen, and welcome to the Fourth Quarter 2018 Xenon Pharmaceuticals Incorporated Financial Results Conference Call. [Operator Instructions] As a reminder, this conferen...

32
Guru FocusMar 6

Xenon Pharmaceuticals Reports 2018 Financial Results and Provides Corporate Update

Multiple Neurology-Focused Products Anticipated to be in Phase 2 or Later Stage Development in 2019 Global XEN1101 Phase 2b Clinical Trial Underway with Data Anticipated in Second Half of 2020 Conference Call at 4:30 pm ET Today BURNABY, British Columbia, March 06, 2019 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (NASDAQ:XENE), a clinical stage biopharmaceutical company, today reported its financial results for the year ended December 31, 2018 and provided a corporate update. Dr. Simon Pimstone, Xe...

9

Earnings

-$0.63
-$0.45
-$0.26
-$0.08
Q2 2017
Q3 2017
Q4 2017
Q1 2018
Q2 2018
Q3 2018
Q4 2018
Q1 2019
Estimated
—
Actual
Expected May 7, After Hours
All investments involve risk and the past performance of a security, or financial product does not guarantee future results or returns. Securities offered through Robinhood Financial LLC, member FINRA/SIPC. To learn more about the information provided on this page, please see our Web Disclosures.